Michael Pfreundschuh, MD, on Treating Lymphoid Malignancies in Children and Adults With the Same Protocols
2015 European Cancer Congress
Michael Pfreundschuh, MD, of Universitaetsklinikum des Saarlandes, summarizes a session he chaired on this topic, which covered Burkitt’s lymphoma as well as lymphoblastic leukemia in children and adults.
Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses the results from a phase III study investigating a multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma (Abstract 17LBA).
Federico Cappuzzo, MD, of Istituto Toscano Tumori-Ospedale Civile Livorno, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss current strategies for treating patients with acquired resistance, and what the future holds for these patients.
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discusses this prospective study of endocrine therapy alone in patients with ER-positive, HER2-negative, node-negative breast cancer (Abstract 5BA).
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
As Chair of the ECC Local Organizing Committee, Christoph Zielinski, MD, of the Medical University Vienna - General Hospital, shares his thoughts on the important goals and presentations of the 2015 Congress.